KALA BIO, INC. Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases
KALA BIO, INC. (KALA) reported Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases of $225.00 thousand for the 12-month period ending 2016-12-31, per its 10-K filed 2018-04-02.
Discontinued › Notes › Fair Value Measures and Disclosures › Fair Value, Assets and Liabilities Measured on Recurring Basis, Unobservable Input Reconciliation › Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases, (Sales), Issuances, (Settlements)
us-gaap:FairValueMeasurementWithUnobservableInputsReconciliationRecurringBasisLiabilityPurchases · last filed 2018-04-02
- KALA BIO, INC. fair value, measurement with unobservable inputs reconciliation, recurring basis, liability, purchases for fiscal 2016 was $225.00K.
| Period end | Fair Value, Measurement with Unobservable Inputs Reconciliation, Recurring Basis, Liability, Purchases 12 month |
|---|---|
| 2016-12-31 | $225.00K 10-K · filed 2018-04-02 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MetaVia Inc. (MTVA) | United States | $0.011B | -0.65 |
| Moleculin Biotech, Inc. (MBRX) | United States | $0.011B | |
| Theriva Biologics, Inc. (TOVX) | United States | $0.011B | |
| Azitra, Inc. (AZTR) | United States | $0.010B | -0.81 |
| Dare Bioscience, Inc. (DARE) | United States | $0.011B | |
| Medicus Pharma Ltd. (MDCX) | $0.010B | ||
| KIORA PHARMACEUTICALS INC (KPRX) | United States | $0.012B | |
| Scienture Holdings, Inc. (SCNX) | United States | $0.012B | -0.38 |
| Aprea Therapeutics, Inc. (APRE) | United States | $0.010B | -0.78 |
| Phio Pharmaceuticals Corp. (PHIO) | United States | $0.012B | -0.92 |